Guard Therapeutics provides update on strategic review
Guard Therapeutics International AB (publ) (“Guard Therapeutics” or the “Company”) hereby provides an update regarding the strategic review that was announced in December 2025.
Guard Therapeutics International AB (publ) (“Guard Therapeutics” or the “Company”) hereby provides an update regarding the strategic review that was announced in December 2025.
Guard Therapeutics International AB (publ) (“Guard Therapeutics” or the “Company”) hereby provides a status update regarding the strategic review that the Company announced through a press release on 4 December 2025. The review, which includes an exploration of potential strategic alternatives, including the identification of potential counterparties for a merger or a reverse takeover (RTO), is progressing according to plan and is expected to be completed during the first quarter of 2026.
Guard Therapeutics (publ) today announced its participation as a partner in a newly funded European research consortium under the 2025 Joint Transnational Call from the European Rare Diseases Research Alliance (ERDERA), aimed at accelerating the development of therapies for rare kidney diseases.
Guard Therapeutics (publ) (“Guard” or the “Company”) announces today that Redeye Aktiebolag (“Redeye”) has been appointed as financial advisor in connection with the strategic review announced by the Company in its press release dated 4 December 2025. The review includes an assessment of potential strategic alternatives, including the identification of possible counterparties for a merger or a reverse acquisition.
Guard Therapeutics (public) (“Guard” or “the Company”) today provides an assessment of the full results from the Phase 2b POINTER study evaluating RMC-035 in patients undergoing open-heart surgery. As previously communicated, the study did not meet its primary or key secondary efficacy endpoints, although promising signals were observed with the 30 mg dose level, particularly in reducing acute kidney injury. Given the overall negative outcome of the study, the Company has decided to discontinue all further development of RMC-035.
Guard Therapeutics (publ) today announced that top-line results from the company’s Phase 2b POINTER study with the investigational drug candidate RMC-035 have been selected for oral presentation on November 6 as a Late-Breaking Clinical Trial at the scientific conference American Society of Nephrology (ASN) Kidney Week 2025 in Houston, TX, USA.
Guard Therapeutics (publ) today announced that the last patient in its ongoing Phase 2b clinical trial, POINTER, has successfully completed the final scheduled follow-up visit 90 days after surgery (last patient last visit). The study is evaluating the company’s drug candidate, RMC-035, as a kidney-protective treatment for patients undergoing open-heart surgery.
Guard Therapeutics (publ) today announced that additional results from the Phase 2 AKITA study with the company’s drug candidate RMC-035 will be presented at the scientific conference Kidney Week 2025 organized by the American Society of Nephrology (ASN), in Houston, TX, USA. The new results are based on post hoc analyses of the previously completed and reported study and provide deeper insights into the potential of RMC-035 to preserve kidney function after open-heart surgery.
Guard Therapeutics (publ) today announced that the company will present at the following investor conferences ahead of the upcoming readout of the Phase 2b POINTER study:
Guard Therapeutics (publ) today announced that the last patient has been successfully enrolled in the company’s ongoing Phase 2b clinical trial, POINTER, evaluating the drug candidate RMC-035 as a kidney-protective therapy in patients undergoing open-heart surgery.
Guard Therapeutics (publ) today announced that the design of its ongoing Phase 2b clinical trial, POINTER, will be presented at the annual congress of the European Renal Association – European Dialysis and Transplant Association (ERA-EDTA) in Vienna, Austria.
Guard Therapeutics announced today that it has reached another key milestone in its ongoing clinical development program. Two-thirds of the approximately 160 planned patients have now been enrolled in the Phase 2b POINTER study, which is evaluating the drug candidate RMC-035 as a kidney-protective treatment for patients undergoing open-heart surgery. This patient cohort serves as the basis for the study’s next major milestone – the second of two independent, company-blinded safety reviews. The outcome of this analysis is expected in the second quarter of 2025.
Guard Therapeutics today announced the formation of a new Scientific Advisory Committee comprising seven globally recognized experts in nephrology and drug development. The committee will play a pivotal role in advising on the company’s late-phase development strategy and the design of the upcoming Phase 3 trial for RMC-035, a kidney protective therapy intended for use in open-heart surgery.
Guard Therapeutics today announced that it has reached the important milestone of enrolling 25% of its target in the phase 2b POINTER study. This trial is evaluating the kidney-protective effects of the investigational drug RMC-035 in patients undergoing open-heart surgery. The next major milestone will be the result of the first of two independent, blinded safety analyses, expected in the first quarter of 2025.
Guard Therapeutics today announced that the first patient in Europe was dosed in the phase 2b POINTER study with the drug candidate RMC-035 as a kidney-protective treatment in open-heart surgery.
Guard Therapeutics today announced that the renowned scientific journal eClinicalMedicine, part of Lancet Discovery Science, has published an article describing the main findings from the company's phase 2 clinical study AKITA with the drug candidate RMC-035, which is being evaluated for the treatment of kidney injury associated with open-heart surgery. The results form the basis for the continued clinical development program with RMC-035 and the design of the recently initiated phase 2b POINTER study.
Guard Therapeutics today announced that the first patient has been dosed in the phase 2b clinical study POINTER with the drug candidate RMC-035 as a kidney-protective treatment in open-heart surgery.
Guard Therapeutics announced today that, through the European application procedure, the company has received authorization from regulatory authorities and ethics committees in Spain, Germany, and the Czech Republic to include patients in the clinical Phase 2b study POINTER with the drug candidate RMC-035 as a kidney-protective treatment in open-heart surgery.
Guard Therapeutics today announced that the scientific journal American Journal of Physiology – Renal Physiology has published an article summarizing important preclinical results of the company's clinical drug candidate RMC-035. The results consistently demonstrate positive effects of RMC-035 in a large number of models for kidney injury and provide clear support for its continued clinical development as a renal protective treatment in open-heart surgery.
Guard Therapeutics [GUARD], a biotechnology company specializing in kidney diseases, announced today that the company conducted a digital R&D Update on January 30, 2024. The presentation included an update on next development steps for the drug candidate RMC-035 and progress within the preclinical development platform of new peptides intended for chronic treatment. A recording of the presentation is available on the company's website.
Guard Therapeutics [GUARD], a biotechnology company specialized in kidney diseases, announced today that the company is organizing a digital R&D Update on January 30, 2024, from 14:00 to 15:30. The company will discuss the results of the completed Phase 2 AKITA study and the continued development plan for the company’s lead candidate RMC-035. New preclinical results from the company's peptide platform will also be presented. In addition to Guard Therapeutics CEO Tobias Agervald and Chief Medical Officer Michael Reusch, Dr. David Goldsmith, Adjunct Professor of Nephrology, King's College, London, will also participate and provide an external perspective on the AKITA results.
Guard Therapeutics International AB (publ) today announces that a Nomination Committee has been appointed in accordance with previous AGM resolutions.
Guard Therapeutics (GUARD), a biotechnology company specializing in kidney diseases, today announced that its late breaking clinical trial abstract has been selected for presentation at the American Society of Nephrology (ASN) Kidney Week in Philadelphia, Pennsylvania, in November 2023. The abstract includes results from the Phase 2 clinical study AKITA evaluating the company’s leading candidate drug RMC-035 as a kidney protective therapy in open-heart surgery.
Guard Therapeutics [GUARD], a biotechnology company specializing in kidney diseases, today announced further information regarding the development strategy for the investigational drug RMC-035. An advisory meeting with the U.S. Food and Drug Administration (FDA) will be requested to explore dose optimization and the framework for a future registrational trial for the prevention of kidney injury in open-heart surgery. The development strategy is based on the recent top-line results of the Phase 2 AKITA study, which demonstrated statistically significant and clinically relevant long-term kidney-protective effects of RMC-035 after open-heart surgery.
Guard Therapeutics [GUARD], a biotechnology company specializing in kidney diseases, announced today that the last patient's last visit (LPLV) in the clinical Phase 2 study AKITA has been completed. The study aims to evaluate the kidney protective effect of the investigational drug RMC-035 in relation to open heart surgery. This milestone means that all patients in the study have been followed up for 90 days after surgery. Top-line results from the study are expected to be communicated in the autumn of 2023 and will thus include the efficacy and safety of RMC-035 throughout the follow-up period.
Guard Therapeutics [GUARD], a biotechnology company specialized in kidney diseases, today announced the full results from the company's Phase 1b clinical study of the investigational drug RMC-035 in patients undergoing kidney transplantation. The study results confirm the previously positive preliminary data analysis and demonstrate favorable pharmacokinetic properties of RMC-035 without any serious adverse effects associated with the investigational drug.
Guard Therapeutics [GUARD] provides updated timelines and additional details on the plan for data analysis in the clinical phase 2 study AKITA, which aims to evaluate the kidney-protective effect of the investigational drug RMC-035 in connection with open heart surgery. The previously reported interim analysis focused on acute drug effects including the incidence of acute kidney injury within 72 hours after surgery. Data collection and analysis for evaluation of efficacy continues for the planned 90-day period for subjects in the study.
Guard Therapeutics [GUARD] today announced positive results of the company's phase 1b clinical trial of the investigational drug RMC-035 in patients undergoing kidney transplantation. The study met its primary objective and demonstrated good pharmacokinetic properties of RMC-035 in this patient population and a favorable safety profile.
Guard Therapeutics [GUARD] today announced that the results from its Phase 1b clinical trial of RMC-035 in patients undergoing open heart surgery have been published in the scientific journal Kidney International Reports. The Phase 1b study met its primary objective and has formed the basis for the company's ongoing Phase 2 clinical trial AKITA.
Guard Therapeutics [GUARD] today announced that the first patient in the US has been dosed with study drug in the ongoing global Phase 2 clinical trial AKITA. The main study objective is to evaluate the kidney-protective effect of RMC-035 in patients who are at increased risk of developing acute kidney injury in connection with open heart surgery.
Guard Therapeutics [GUARD] today announced that 134 of the planned 268 patients have been dosed in the global randomized, double-blinded and placebo-controlled Phase 2 clinical trial (AKITA). The AKITA study has been designed to evaluate the kidney-protective effects of the investigational drug RMC-035 in conjunction with open heart surgery. An interim analysis will be conducted by an independent Data Monitoring Committee (DMC) who will provide a recommendation in April regarding the continuation of the study.
On September 21, 2022, Guard Therapeutics hosted a Capital Markets Day at Erik Penser Bank in Stockholm to provide an update on the company's development projects and the clinical strategy for the investigational drug RMC-035 (ROSgard). The presentations were recorded and are now available on the company's website.
Guard Therapeutics today announces that the first patient has been dosed in a Phase 1b clinical trial of the investigational drug RMC-035 (ROSgard) in kidney transplantation. The company has thus achieved an important milestone by expanding the clinical development program to a second indication where RMC-035 has the potential to protect against acute kidney injuries. Full study results are expected to be available in the first half of 2023.
Guard Therapeutics invites current and potential investors to a capital markets day where the company will inform the audience on main development projects and clinical strategy for the investigational drug RMC-035 (ROSgard). The event will take place on September 21, 2022, 12:00 p.m. CET, at Erik Penser Bank in Stockholm and will be streamed live.
Guard Therapeutics today provides an update on the plan for the company's global, clinical phase 2 study of ROSgard in patients undergoing open heart surgery with additional risk factors to develop acute kidney injury. The study aims to evaluate the renal protective treatment effect of ROSgard based on several outcome measures, and is anticipated to provide a comprehensive data set to support further clinical development including the design of a subsequent registration study. The phase 2 study is called AKITA and is expected to provide blinded interim results in the first quarter of 2023 at topline results during the later part of 2023. Guard Therapeutics CEO, Tobias Agervald, presents the study design in a video interview that is available via link further down in this press release.
Guard Therapeutics today announces that the first patient has been dosed in the company's global phase 2 clinical trial of ROSgard. The study is conducted in patients who undergo open heart surgery and thus are at risk of developing acute kidney injury. The results are expected to provide conclusive information on the treatment effect of the investigational drug in this patient group and to guide the design of a subsequent pivotal study.
Guard Therapeutics today announces that the Canadian health authority (Health Canada) has approved the company’s application to conduct and include patients in Canada in the comprehensive phase 2 study of ROSgard, an investigational drug being developed for the prevention and treatment of acute kidney injury. This global study is planned to be conducted in Europe and North America and has since earlier been approved by the German medicines regulator.
Guard Therapeutics announces today that the German medicines regulator, the Federal Institute for Drugs and Medical Devices (BfArM), has approved the company’s application to conduct a comprehensive clinical phase 2 study of ROSgard, an investigational drug being developed for the prevention and treatment of acute kidney injury. The global study is planned to be conducted in Europe and North America under the guidance of Prof. Dr. Alexander Zarbock at Münster University Hospital, Germany.
Guard Therapeutics AB (publ.) announces that the European Patent Office (EPO) today has granted a patent for the company’s biological investigational drug ROSgard, both as a product and for its medical use. The patent provides protection in Europe until 2037.
Guard Therapeutics announces today that all 12 patients have been included in the company’s clinical phase 1b study of ROSgard, which is being conducted in people undergoing open heart surgery who have additional risk factors for acute kidney injury. The study is being conducted at the University Hospital in Münster, Germany. Top-line results are expected to be presented in September 2021.
Guard Therapeutics today announces that the company has established an external Scientific Advisory Committee (SAC) initially consisting of five global experts. The committee’s main task in the near future will be to contribute their expertise in the final design of the planned phase 2 study of the company’s investigational drug ROSgard in patients undergoing cardiac surgery.
Guard Therapeutics AB (publ.) today announces that the United States Patent and Trademark Office (USPTO) has granted the company’s patent application no. 16/085,500 directed to the biological investigational drug ROSgard as product (composition of matter). The granted patent follows the Notice of Allowance that was issued and communicated in December 2020.
Guard Therapeutics today announces that the first patient has been dosed in a phase 1b study of the company’s investigational drug ROSgard. The study is being conducted in patients undergoing open heart surgery who have additional risk factors for acute kidney injury. The phase 1b study is being conducted at Münster University Hospital in Germany.
Guard Therapeutics has obtained patent protection in Australia for their biological investigational drug ROSgard, both as product and for its use in medicine.
Guard Therapeutics today announced positive top line results from the final and highest dosage group as part of a clinical phase 1a study where single ascending doses (SAD) of the investigational drug ROSgard™ were administered to healthy subjects. ROSgard also demonstrated good pharmacokinetic properties and a favourable safety profile at this dosage level, which is higher than the one that is expected to be used in future patient studies. The next stage in the phase 1a programme is to study ROSgard in multiple ascending doses (MAD).